drugset / Trial / NCT02140047
Exploratory Clinical Study of MT-2301
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to evaluate efficacy and safety of MT-2301 when co-administered with DPT-IPV using ActHIB® as a control in healthy infants.
Timeline
- Start
- 2014-04
- Primary completion
- 2015-01
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ActHIB | Vaccine | 0.5 ml | Subcutaneous |
| Subject | MT-2301 | Unknown | 0.25 ml | Subcutaneous |
| Subject | MT-2301 | Unknown | 0.5 ml | Subcutaneous |
| Background | DPT-IPV | Vaccine | — | Subcutaneous |